Last updated: April 25, 2026
Who supplies pharmaceutical-grade hydrocortisone?
Common upstream suppliers of active pharmaceutical ingredient (API) hydrocortisone and hydrocortisone derivatives used in topical and ophthalmic products include:
| Supplier / Group |
API(s) commonly marketed |
Typical product scope |
| Hikma Pharmaceuticals (API segment via manufacturing network) |
Hydrocortisone |
Branded and generic API supply through internal and contract manufacturing |
| Teva API / Teva group network |
Hydrocortisone (where offered) |
Generic API supply via established GMP networks |
| Aurobindo Pharma (API network) |
Hydrocortisone |
API supply via internal manufacturing and CMOs |
| Mylan (through legacy generic API supply networks) |
Hydrocortisone |
Generic supply chains depending on portfolio |
| Amneal / Sagent legacy API networks |
Hydrocortisone |
API supply depending on market availability |
| CordenPharma (CMO/route to API depending on customer) |
Hydrocortisone (intermediates and/or API depending on scope) |
Contract development/manufacturing for steroids and related intermediates |
| Local and regional GMP manufacturers (EU/US/India/China) |
Hydrocortisone |
API availability varies by country and current registration status |
Supply-chain reality for hydrocortisone: it is widely sourced from multiple GMP geographies because it is older, widely manufactured, and used across topical, otic, and ophthalmic formats. Sourcing decisions typically track DMF/CEP availability, impurity profile, and regulatory listing (EU CEP or US DMF status).
Who supplies neomycin sulfate (API and base-salt equivalents)?
Neomycin sulfate sourcing commonly includes both direct API suppliers and contract manufacturing networks that produce antibiotic APIs and antibiotic-related salts. Typical supplier categories:
| Supplier / Group |
API(s) commonly marketed |
Typical product scope |
| Aurobindo Pharma |
Neomycin sulfate |
API supply through internal/outsourced GMP manufacturing |
| Teva group network |
Neomycin sulfate |
Generic API supply depending on portfolio |
| Hikma / other generic API networks |
Neomycin sulfate |
Market-dependent API availability |
| Specialty antibiotic API manufacturers (India, China, EU) |
Neomycin sulfate |
Antibiotic-focused GMP supply chains |
| CMOs handling antibiotics and fermentation-derived APIs (route dependent) |
Neomycin sulfate (API or intermediates depending on scope) |
Contract manufacturing and purification work |
Supply-chain reality for neomycin sulfate: it is fermentation-derived and sensitive to consistent upstream conditions. Buyers typically require evidence of microbial and chemical impurity control, consistent sulfate salt spec, and stable particle and assay specs for downstream blend performance.
Who supplies polymyxin B sulfate (API and related salts)?
Polymyxin B sulfate is also widely sourced through antibiotic-focused API producers and GMP contract manufacturing. Typical supplier categories:
| Supplier / Group |
API(s) commonly marketed |
Typical product scope |
| Specialty antibiotic API manufacturers |
Polymyxin B sulfate |
Direct API supply for topical and otic uses |
| Teva / generic API networks |
Polymyxin B sulfate |
Portfolio-dependent supply via GMP networks |
| Aurobindo and other generic API groups |
Polymyxin B sulfate |
Generic API supply where offered |
| CMOs with antibiotic capabilities |
Polymyxin B sulfate (scope dependent) |
Production and purification under contract |
Supply-chain reality for polymyxin B sulfate: it has tight specs tied to potency, impurity spectrum, and salt form. Customers usually source from vendors who can support controlled impurity panels and consistent potency testing.
What matters when selecting suppliers for these three APIs together?
For fixed-dose combinations such as hydrocortisone plus neomycin sulfate plus polymyxin B sulfate (commonly topical/otic formats), sourcing is driven by three operational constraints: (1) documentation readiness, (2) lot-to-lot consistency, and (3) ability to support regulatory filings.
Documentation and regulatory readiness (typical requirements)
| Requirement |
What buyers check |
| Regulatory filing support |
US DMF or EU CEP coverage for the specific API and salt form |
| GMP status |
Approved inspection history for the manufacturing site(s) |
| Analytical package |
Assay, impurities, water content, residual solvents (where relevant), sulfate form confirmation |
| Stability support |
Requested stability protocol assumptions for the API and for downstream formulation work |
Quality attributes that become make-or-break in combination products
| API |
Quality attribute that drives supplier selection |
| Hydrocortisone |
Steroid-related impurity profile and polymorph or crystallinity behavior |
| Neomycin sulfate |
Sulfate salt form confirmation, fermentation impurity profile, and microbial controls |
| Polymyxin B sulfate |
Potency and impurity spectrum consistency across lots |
Where these supply chains typically originate (by geography)?
API manufacturing and antibiotic API supply are concentrated in established GMP clusters, with the largest footprints in:
- India (broad generic API production including antibiotics and steroids)
- China (high volume API manufacturing across many categories, including antibiotic APIs)
- EU (select companies and CMO networks with CEP or EU documentation support)
- US (more limited for these specific APIs as API origin shifts to global GMP sources, but DMF/registration handling may involve US-based documentation)
Actionable supplier-screening approach (fast, procurement-ready)
-
Lock the exact salt form and grade
Confirm the buyer-spec line item matches neomycin sulfate and polymyxin B sulfate (not base or alternative forms), and hydrocortisone spec (including whether it is hydrocortisone itself or a defined derivative).
-
Map regulatory coverage first
Shortlist suppliers with the strongest probability of supporting filings in the target market using DMF/CEP equivalents and a complete analytical and manufacturing control package.
-
Prioritize antibiotic-potency and impurity controls
In combination products, antibiotic APIs often drive batch release risk. Ensure the supplier can supply consistent potency and impurity profiles for neomycin and polymyxin.
-
Run a technical qualification on the first commercial lots
Require qualification runs covering identity, assay, impurity panel, and stability behavior under the planned formulation packaging approach.
Key Takeaways
- Hydrocortisone, neomycin sulfate, and polymyxin B sulfate are widely available from generic API networks and antibiotic-focused API manufacturers; supplier selection hinges on DMF/CEP documentation, impurity control, and salt form/potency consistency.
- For neomycin sulfate and polymyxin B sulfate, the strongest procurement differentiator is usually potency and impurity spectrum repeatability across lots, supported by GMP inspection history and complete analytical packages.
- For combination products that include all three APIs, buyers should screen suppliers as a set based on regulatory readiness plus lot-to-lot quality stability, not just price.
FAQs
1) Can one supplier provide hydrocortisone, neomycin sulfate, and polymyxin B sulfate simultaneously?
Yes, but it is not guaranteed. Many programs consolidate by market availability and documentation fit rather than relying on a single-source supplier for all three APIs.
2) What documentation is most important for these APIs?
Typically US DMF or EU CEP-equivalent coverage, plus a full analytical data package and GMP manufacturing-site documentation.
3) Why are neomycin and polymyxin sulfate harder to qualify than hydrocortisone?
Neomycin and polymyxin are fermentation-derived antibiotic APIs where supplier-to-supplier differences can show up in potency and impurity profiles, which directly affects batch release and formulation consistency.
4) Are there common quality pitfalls in sulfate salt APIs?
Yes. Buyers commonly scrutinize salt form confirmation, sulfate-related assay behavior, and the impurity panel for sulfate-linked and process-related impurities.
5) Do contract manufacturers (CMOs) play a role in API sourcing for these drugs?
Yes. Some customers source via CMO networks for route optimization or scale-up, but final supplier eligibility still depends on regulatory documentation and GMP acceptance for the actual commercial API.
References
[1] US FDA. “Drug Master Files (DMFs).” FDA. https://www.fda.gov/drugs/drug-master-files-dmfs
[2] European Medicines Agency. “CEP (Certificate of Suitability) database.” EMA. https://www.ema.europa.eu/en/human-regulatory/research-development/cep-certificate-suitability/pharmaceutical-manufacturers-and-their-cep-approved-substances-0
[3] FDA. “Current Good Manufacturing Practice (CGMP) for Finished Pharmaceuticals.” FDA. https://www.fda.gov/drugs/current-good-manufacturing-practice-cgmp-finished-pharmaceuticals
